India's drugmaker Ranbaxy swings into quarterly net loss

October 29, 2013

India's biggest generic drugmaker Ranbaxy Laboratories swung into a net loss in the third quarter ended September from a profit a year earlier, owing to a weak rupee and foreign exchange losses.

The Indian firm, majority-owned by Japan's Daiichi Sankyo, posted a consolidated of 4.5 billion rupees ($73 million), against a 7.5 billion rupee profit a year earlier.

Adverse currency movements in the quarter dragged the company into the red, Ranbaxy said.

"There was a net charge of 3.6 billion rupees during the quarter on account of forex items," it added.

Sales for Ranbaxy, headquartered in Gurgaon near New Delhi, rose just 3.05 percent to 27.5 billion rupees in the quarter from a year earlier, just below analyst expectations.

"The company continues to grow in its focus branded markets in Asia, East Europe, CIS (Commonwealth of Independent States) and Africa," said Arun Sawhney, managing director of Ranbaxy.

Ranbaxy has been hit by controversy after the US Food and Drug Administration placed bans on drugs from three of its manufacturing plants.

In May, Ranbaxy had pleaded guilty to US charges of selling adulterated antibiotic, epilepsy and other drugs, and agreed to a record $500 million fine.

The firm assured shareholders in September that it was taking "stringent steps" to resolve a US ban on imports of medicines made at its newly renovated showcase plant in northern India.

Ranbaxy is more than 60 percent owned by Japan's Daiichi Sankyo, which bought the firm in 2008 believing its dominance in cheaper generic medicines and developing markets would help the Japanese firm grow sales as Daiichi's drugs came off patent.

Explore further: Ranbaxy taking 'stringent steps' to end US FDA ban

Related Stories

Ranbaxy taking 'stringent steps' to end US FDA ban

September 21, 2013
India's biggest drugmaker by sales, Ranbaxy Laboratories, has assured shareholders it is taking "stringent steps" to resolve a US ban on imports of medicines made at its newly renovated showcase plant.

Indian drugmaker Ranbaxy faces new US regulation woes (Update 2)

September 16, 2013
Shares in Indian generic drugs giant Ranbaxy Laboratories crashed by as much as 35 percent on Monday after the US Food and Drug Administration suspended imports from one of its factories.

India's Ranbaxy promises to address issues over US ban

September 17, 2013
India's Ranbaxy Laboratories, one of world's biggest generic drug makers, said Tuesday it would take "all necessary steps" to help lift an import ban by the US health regulator on one of its factories.

More pain for Japan's Daiichi hit by Ranbaxy fraud

June 9, 2013
Daiichi Sankyo believed it had scored a coup in 2008 when it outbid rivals to buy Indian generics giant Ranbaxy for $4.6 billion but its foray into the high-growth copycat drugs arena has brought the Japanese drugmaker only ...

India says its drugs safe after generics fraud

June 3, 2013
India, known as the "pharmacy to the world", Monday defended its lucrative generic drug industry as safe and strongly regulated after the nation's biggest drug firm pleaded guilty to US charges of making adulterated medicines.

Swiss pharma Novartis ups full-year sales outlook (Update)

October 22, 2013
Swiss pharmaceutical giant Novartis AG raised its full-year sales outlook because of delays in generic competition to its blockbuster blood pressure drug Diovan, even though it said negative currency trends contributed to ...

Recommended for you

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.